us-gaap:ServiceMember us-gaap:ServiceMember us-gaap:ServiceMember 0001650664 false--12-31 2021 Q3 0 0 us-gaap:ServiceMember P1Y 0001650664 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001650664 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001650664 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001650664 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001650664 edit:AtMarketOfferingMember 2021-05-01 2021-09-30 0001650664 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001650664 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001650664 us-gaap:RetainedEarningsMember 2021-09-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001650664 us-gaap:RetainedEarningsMember 2021-06-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001650664 2021-06-30 0001650664 us-gaap:RetainedEarningsMember 2021-03-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001650664 2021-03-31 0001650664 us-gaap:RetainedEarningsMember 2020-12-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001650664 us-gaap:RetainedEarningsMember 2020-09-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001650664 us-gaap:RetainedEarningsMember 2020-06-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001650664 2020-06-30 0001650664 us-gaap:RetainedEarningsMember 2020-03-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001650664 2020-03-31 0001650664 us-gaap:RetainedEarningsMember 2019-12-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001650664 us-gaap:CommonStockMember 2021-09-30 0001650664 us-gaap:CommonStockMember 2021-06-30 0001650664 us-gaap:CommonStockMember 2021-03-31 0001650664 us-gaap:CommonStockMember 2020-12-31 0001650664 us-gaap:CommonStockMember 2020-09-30 0001650664 us-gaap:CommonStockMember 2020-06-30 0001650664 us-gaap:CommonStockMember 2020-03-31 0001650664 us-gaap:CommonStockMember 2019-12-31 0001650664 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001650664 us-gaap:EmployeeStockOptionMember 2020-12-31 0001650664 srt:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-09-30 0001650664 srt:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-09-30 0001650664 us-gaap:RestrictedStockMember 2020-12-31 0001650664 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0001650664 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001650664 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001650664 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001650664 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001650664 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-09-30 0001650664 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001650664 us-gaap:FurnitureAndFixturesMember 2021-09-30 0001650664 us-gaap:ConstructionInProgressMember 2021-09-30 0001650664 us-gaap:ComputerEquipmentMember 2021-09-30 0001650664 edit:LaboratoryEquipmentMember 2021-09-30 0001650664 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001650664 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001650664 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001650664 us-gaap:ConstructionInProgressMember 2020-12-31 0001650664 us-gaap:ComputerEquipmentMember 2020-12-31 0001650664 edit:LaboratoryEquipmentMember 2020-12-31 0001650664 edit:CommitmentToReimburseLicensorMember 2021-07-01 2021-09-30 0001650664 edit:CommitmentToReimburseLicensorMember 2021-01-01 2021-09-30 0001650664 edit:CommitmentToReimburseLicensorMember 2020-07-01 2020-09-30 0001650664 edit:CommitmentToReimburseLicensorMember 2020-01-01 2020-09-30 0001650664 us-gaap:OverAllotmentOptionMember 2021-02-01 2021-02-28 0001650664 us-gaap:IPOMember 2021-01-01 2021-01-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001650664 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001650664 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001650664 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001650664 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001650664 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001650664 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001650664 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001650664 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0001650664 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001650664 us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-12-31 0001650664 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001650664 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001650664 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001650664 us-gaap:RestrictedStockMember 2021-09-30 0001650664 us-gaap:EmployeeStockOptionMember 2021-09-30 0001650664 2020-09-30 0001650664 2019-12-31 0001650664 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001650664 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001650664 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001650664 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-09-30 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-09-30 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001650664 us-gaap:MoneyMarketFundsMember 2021-09-30 0001650664 us-gaap:MoneyMarketFundsMember 2020-12-31 0001650664 us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001650664 us-gaap:CommercialPaperMember 2020-12-31 0001650664 us-gaap:USTreasurySecuritiesMember 2021-09-30 0001650664 us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-09-30 0001650664 us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001650664 us-gaap:CommercialPaperMember 2021-09-30 0001650664 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001650664 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001650664 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001650664 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001650664 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001650664 us-gaap:RestrictedStockMember 2021-07-01 2021-09-30 0001650664 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001650664 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001650664 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001650664 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0001650664 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001650664 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001650664 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001650664 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001650664 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001650664 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001650664 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001650664 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001650664 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001650664 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001650664 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001650664 2021-07-01 2021-09-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001650664 2021-04-01 2021-06-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001650664 2021-01-01 2021-03-31 0001650664 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001650664 2020-07-01 2020-09-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001650664 2020-04-01 2020-06-30 0001650664 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001650664 2020-01-01 2020-03-31 0001650664 edit:AtMarketOfferingMember 2021-05-31 0001650664 srt:MinimumMember 2021-01-01 2021-09-30 0001650664 srt:MaximumMember 2021-01-01 2021-09-30 0001650664 2020-01-01 2020-09-30 0001650664 2021-09-30 0001650664 2020-12-31 0001650664 2021-11-05 0001650664 2021-01-01 2021-09-30 xbrli:shares iso4217:USD edit:security iso4217:USD xbrli:shares edit:item

Table of Contents

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

​

OR

​

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ________

​

​

Commission File Number 001-37687

EDITAS MEDICINE, INC.

(Exact name of registrant as specified in its charter)

​

​ | ​ | ​
Delaware (State or other jurisdiction of incorporation or organization) | ​ | 46-4097528 (I.R.S. Employer Identification No.)
​ | ​ | ​
11 Hurley Street Cambridge, Massachusetts (Address of principal executive offices) | ​ | 02141 (Zip Code)

​

(617) 401-9000

(Registrant’s telephone number, including area code)

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​
​ | ​ | ​
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value per share | EDIT | The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer | ⌧ | Accelerated filer | ◻
​ | ​ | ​ | ​
Non-accelerated filer | ◻ | Smaller reporting company | ☐
​ | ​ | ​ Emerging growth company | ​ ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.◻

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

​

The number of shares of Common Stock outstanding as of November 5, 2021 was 68,398,540.

​

​

Table of Contents

​

Editas Medicine, Inc.

TABLE OF CONTENTS

​

|  | ​ | ​
|  | Page
​ | ​ | ​
PART I. FINANCIAL INFORMATION | ​ | 3
​ | ​ | ​ | ​
Item 1. | Financial Statements (unaudited) | ​ | 3
​ | Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020 | ​ | 3
​ | Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021 | ​ | 4
​ | Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2021 and 2020 | ​ | 5
​ | Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and 2020 | ​ | 6
​ | Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 | ​ | 8
​ | Notes to Condensed Consolidated Financial Statements | ​ | 9
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | ​ | 17
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | ​ | 30
Item 4. | Controls and Procedures | ​ | 31
​ | ​ | ​
PART II. OTHER INFORMATION | ​ | 32
​ | ​ | ​ | ​
Item 1. | Legal Proceedings | ​ | 32
Item 1A. | Risk Factors | ​ | 32
Item 6. | Exhibits | ​ | 35
​ | ​ | ​
Signatures | ​ | 36
​ | ​ | ​

​

2

Table of Contents

PART I. FINANCIAL INFORMATION

​

Item 1. Financial Statements.

Editas Medicine, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(amounts in thousands, except share and per share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | December 31,
​ | ​ | 2021 | ​ | 2020
ASSETS | ​ | ​ | ​ | ​ | ​ | ​
Current assets: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 259,884 | ​ | $ | 139,682
Marketable securities | ​ | ​ | 297,957 | ​ | ​ | 262,428
Accounts receivable | ​ |  | 251 | ​ |  | 6,048
Prepaid expenses and other current assets | ​ |  | 9,516 | ​ |  | 10,929
Total current assets | ​ |  | 567,608 | ​ |  | 419,087
Marketable securities | ​ | ​ | 99,198 | ​ | ​ | 109,664
Property and equipment, net | ​ |  | 15,631 | ​ |  | 14,020
Right-of-use assets | ​ | ​ | 27,801 | ​ | ​ | 25,128
Restricted cash and other non-current assets | ​ |  | 6,781 | ​ |  | 4,703
Total assets | ​ | $ | 717,019 | ​ | $ | 572,602
LIABILITIES AND STOCKHOLDERS’ EQUITY | ​ | ​ | ​ | ​ | ​ | ​
Current liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable | ​ | $ | 3,402 | ​ | $ | 6,408
Accrued expenses | ​ |  | 14,575 | ​ |  | 24,046
Deferred revenue, current | ​ | ​ | 22,667 | ​ | ​ | 20,943
Operating lease liabilities | ​ | ​ | 10,263 | ​ | ​ | 6,811
Total current liabilities | ​ |  | 50,907 | ​ |  | 58,208
Operating lease liabilities, net of current portion | ​ | ​ | 18,430 | ​ | ​ | 19,324
Deferred revenue, net of current portion | ​ | ​ | 60,888 | ​ | ​ | 73,984
Other non-current liabilities | ​ |  | — | ​ |  | 27,500
Total liabilities | ​ | ​ | 130,225 | ​ | ​ | 179,016
Stockholders’ equity | ​ | ​ | ​ | ​ | ​ | ​
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding | ​ |  | — | ​ |  | —
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,392,659 and 62,689,457 shares issued, and 68,320,659 and 62,563,457 shares outstanding at September 30, 2021 and December 31, 2020, respectively | ​ |  | 7 | ​ |  | 6
Additional paid-in capital | ​ |  | 1,403,114 | ​ |  | 1,058,823
Accumulated other comprehensive loss | ​ | ​ | (64) | ​ | ​ | (46)
Accumulated deficit | ​ |  | (816,263) | ​ |  | (665,197)
Total stockholders’ equity | ​ | ​ | 586,794 | ​ | ​ | 393,586
Total liabilities and stockholders’ equity | ​ | $ | 717,019 | ​ | $ | 572,602

​

The accompanying notes are an integral part of the condensed consolidated financial statements.

​

3

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statement of Operations

(unaudited)

(amounts in thousands, except share and per share data)

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2021 |  | 2020 |  | 2021 |  | 2020
Collaboration and other research and development revenues | ​ | $ | 6,197 | ​ | $ | 62,841 | ​ | $ | 13,075 | ​ | $ | 79,313
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ |  | 29,265 | ​ |  | 33,916 | ​ |  | 104,954 | ​ |  | 96,492
General and administrative | ​ |  | 16,185 | ​ |  | 19,936 | ​ |  | 59,657 | ​ |  | 51,789
Total operating expenses | ​ |  | 45,450 | ​ |  | 53,852 | ​ |  | 164,611 | ​ | ​ | 148,281
Operating (loss) income | ​ |  | (39,253) | ​ |  | 8,989 | ​ |  | (151,536) | ​ |  | (68,968)
Other income (expense), net: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other income (expense), net | ​ |  | 19 | ​ |  | (1,396) | ​ |  | 38 | ​ |  | 13,114
Interest income, net | ​ | ​ | 152 | ​ | ​ | 226 | ​ | ​ | 432 | ​ | ​ | 2,377
Total other income (expense), net | ​ |  | 171 | ​ |  | (1,170) | ​ |  | 470 | ​ |  | 15,491
Net (loss) income | ​ | $ | (39,082) | ​ | $ | 7,819 | ​ | $ | (151,066) | ​ | $ | (53,477)
Net (loss) income per share, basic | ​ | $ | (0.57) | ​ | $ | 0.13 | ​ | $ | (2.24) | ​ | $ | (0.93)
Net (loss) income per share, diluted | ​ | $ | (0.57) | ​ | $ | 0.12 | ​ | $ | (2.24) | ​ | $ | (0.93)
Weighted-average common shares outstanding, basic | ​ | ​ | 68,219,742 | ​ | ​ | 62,144,118 | ​ |  | 67,371,246 | ​ |  | 57,377,581
Weighted-average common shares outstanding, diluted | ​ | ​ | 68,219,742 | ​ | ​ | 62,697,173 | ​ | ​ | 67,371,246 | ​ | ​ | 57,377,581

​

​

The accompanying notes are an integral part of the condensed consolidated financial statements.

​

4

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statements of Comprehensive (Loss) Income

(unaudited)

(amounts in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ | ​ | 2021 | ​ | 2020 | ​ | 2021 | ​ | 2020
Net (loss) income | ​ | $ | (39,082) | ​ | $ | 7,819 | ​ | $ | (151,066) | ​ | $ | (53,477)
Other comprehensive (loss) income: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Unrealized gain (loss) on marketable debt securities | ​ |  | 7 | ​ |  | (231) | ​ |  | (18) | ​ |  | (155)
Comprehensive (loss) income | ​ | $ | (39,075) | ​ | $ | 7,588 | ​ | $ | (151,084) | ​ | $ | (53,632)

​

The accompanying notes are an integral part of the condensed consolidated financial statements.

​

​

​

​

​

5

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(amounts in thousands, except share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | Accumulated |  | ​ |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | Other | ​ | Other | ​ | Total
​ | ​ | Common Stock | ​ | Paid-In | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’
​ | ​ | Shares |  | Amount | ​ | Capital | ​ | Loss | ​ | Deficit | ​ | Equity
Balance at December 31, 2020 | ​ | 62,563,457 | ​ | $ | 6 | ​ | $ | 1,058,823 | ​ | $ | (46) | ​ | $ | (665,197) | ​ | $ | 393,586
Issuance of common stock for public offering | ​ | 4,025,000 | ​ | ​ | 1 | ​ | ​ | 249,458 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 249,459
Issuance of common stock for success payment | ​ | 303,599 | ​ | ​ | — | ​ | ​ | 27,500 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 27,500
Exercise of stock options | ​ | 501,162 | ​ | ​ | — | ​ | ​ | 12,002 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 12,002
Vesting of restricted common stock awards | ​ | 79,397 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Stock-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 12,204 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 12,204
Unrealized loss on marketable debt securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (27) | ​ | ​ | — | ​ | ​ | (27)
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (56,728) | ​ | ​ | (56,728)
Balance at March 31, 2021 | ​ | 67,472,615 | ​ | $ | 7 | ​ | $ | 1,359,987 | ​ | $ | (73) | ​ | $ | (721,925) | ​ | $ | 637,996
Exercise of stock options | ​ | 629,973 | ​ | ​ | — | ​ | ​ | 16,567 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 16,567
Stock-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 13,526 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 13,526
Vesting of restricted common stock awards | ​ | 37,790 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Purchase of common stock under benefit plans | ​ | 19,408 | ​ | ​ | — | ​ | ​ | 526 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 526
Unrealized gain on marketable debt securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2 | ​ | ​ | — | ​ | ​ | 2
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (55,256) | ​ | ​ | (55,256)
Balance at June 30, 2021 | ​ | 68,159,786 | ​ | $ | 7 | ​ | $ | 1,390,606 | ​ | $ | (71) | ​ | $ | (777,181) | ​ | $ | 613,361
Exercise of stock options | ​ | 86,985 | ​ | ​ | — | ​ | ​ | 2,496 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,496
Stock-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 10,012 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 10,012
Vesting of restricted common stock awards | ​ | 73,888 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Unrealized gain on marketable debt securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7 | ​ | ​ | — | ​ | ​ | 7
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (39,082) | ​ | ​ | (39,082)
Balance at September 30, 2021 | ​ | 68,320,659 | ​ | $ | 7 | ​ | $ | 1,403,114 | ​ | $ | (64) | ​ | $ | (816,263) | ​ | $ | 586,794

​

​

6

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ |  | ​ |  | ​
​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | Accumulated |  | ​ |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | Other | ​ | Other | ​ | Total
​ | ​ | Common Stock | ​ | Paid-In | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’
​ | ​ | Shares |  | Amount | ​ | Capital | ​ | Income (Loss) | ​ | Deficit | ​ | Equity
Balance at December 31, 2019 | ​ | 54,355,798 | ​ | $​ | 5 | ​ | $​ | 811,546 | ​ | $​ | 107 | ​ | $​ | (549,221) | ​ | $ | 262,437
Exercise of stock options | ​ | 233,208 | ​ | ​ | — | ​ | ​ | 3,047 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,047
Vesting of restricted common stock awards | ​ | 213,393 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Stock-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 6,220 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,220
Unrealized gain on marketable debt securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 587 | ​ | ​ | — | ​ | ​ | 587
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (37,724) | ​ | ​ | (37,724)
Balance at March 31, 2020 | ​ | 54,802,399 | ​ | $ | 5 | ​ | $ | 820,813 | ​ | $ | 694 | ​ | $ | (586,945) | ​ | $ | 234,567
Exercise of stock options | ​ | 355,812 | ​ | ​ | — | ​ | ​ | 6,839 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,839
Issuance of common stock for public offering | ​ | 6,900,000 | ​ | ​ | 1 | ​ | ​ | 203,681 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 203,682
Stock-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 5,417 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,417
Vesting of restricted common stock awards | ​ | 30,194 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Purchase of common stock under benefit plans | ​ | 15,244 | ​ | ​ | — | ​ | ​ | 350 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 350
Unrealized loss on marketable debt securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (511) | ​ | ​ | — | ​ | ​ | (511)
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (23,572) | ​ | ​ | (23,572)
Balance at June 30, 2020 | ​ | 62,103,649 | ​ | $ | 6 | ​ | $ | 1,037,100 | ​ | $ | 183 | ​ | $ | (610,517) | ​ | $ | 426,772
Exercise of stock options | ​ | 48,312 | ​ | ​ | — | ​ | ​ | 947 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 947
Stock-based compensation expense | ​ | — | ​ | ​ | — | ​ | ​ | 5,845 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,845
Vesting of restricted common stock awards | ​ | 35,739 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Unrealized loss on marketable debt securities | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (231) | ​ | ​ | — | ​ | ​ | (231)
Net income | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,819 | ​ | ​ | 7,819
Balance at September 30, 2020 | ​ | 62,187,700 | ​ | $ | 6 | ​ | $ | 1,043,892 | ​ | $ | (48) | ​ | $ | (602,698) | ​ | $ | 441,152

​

​

​

​

​

​

The accompanying notes are an integral part of the condensed consolidated financial statements.

7

Table of Contents

Editas Medicine, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(amounts in thousands)

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended
​ | ​ | September 30,
​ |  | 2021 |  | 2020
Cash flow from operating activities | ​ | ​ | ​ | ​ | ​ | ​
Net loss | ​ | $ | (151,066) | ​ | $ | (53,477)
Adjustments to reconcile net loss to net cash used in operating activities: | ​ | ​ | ​ | ​ | ​ | ​
Stock-based compensation expense | ​ |  | 35,742 | ​ |  | 17,483
Depreciation | ​ |  | 3,542 | ​ |  | 2,776
Unrealized gain on corporate equity securities | ​ | ​ | — | ​ | ​ | (13,109)
Other non-cash items, net | ​ |  | 1,332 | ​ |  | (285)
Changes in operating assets and liabilities: | ​ |  | ​ | ​ |  | ​
Accounts receivable | ​ | ​ | 5,797 | ​ | ​ | (637)
Prepaid expenses and other current assets | ​ | ​ | 1,414 | ​ | ​ | (4,181)
Right-of-use assets | ​ | ​ | 7,080 | ​ | ​ | 2,363
Other non-current assets | ​ | ​ | (2,077) | ​ | ​ | 106
Accounts payable | ​ | ​ | (2,978) | ​ | ​ | (447)
Accrued expenses | ​ | ​ | (9,439) | ​ | ​ | (2,391)
Deferred revenue | ​ |  | (11,372) | ​ |  | (86,026)
Operating lease liabilities | ​ |  | (7,196) | ​ |  | (2,371)
Other current and non-current liabilities | ​ | ​ | — | ​ | ​ | 453
Net cash used in operating activities | ​ |  | (129,221) | ​ |  | (139,743)
Cash flow from investing activities | ​ | ​ | ​ | ​ | ​ | ​
Purchases of property and equipment | ​ |  | (5,132) | ​ | ​ | (5,786)
Proceeds from the sale of equipment | ​ | ​ | — | ​ | ​ | 21
Purchases of marketable securities | ​ | ​ | (304,570) | ​ | ​ | (300,363)
Proceeds from maturities of marketable securities | ​ | ​ | 278,076 | ​ | ​ | 274,500
Net cash used in investing activities | ​ |  | (31,626) | ​ |  | (31,628)
Cash flow from financing activities | ​ | ​ | ​ | ​ | ​ | ​
Proceeds from offering of common stock, net of issuance costs | ​ | ​ | 249,458 | ​ | ​ | 203,839
Proceeds from exercise of stock options | ​ | ​ | 31,065 | ​ | ​ | 10,833
Issuance of common stock under benefit plans | ​ | ​ | 526 | ​ | ​ | 350
Net cash provided by financing activities | ​ |  | 281,049 | ​ |  | 215,022
Net increase in cash, cash equivalents, and restricted cash | ​ |  | 120,202 | ​ | ​ | 43,651
Cash, cash equivalents, and restricted cash, beginning of period | ​ |  | 143,559 | ​ | ​ | 239,802
Cash, cash equivalents, and restricted cash, end of period | ​ | $ | 263,761 | ​ | $ | 283,453
Supplemental disclosure of cash and non-cash activities: | ​ | ​ | ​ | ​ | ​ | ​
Fixed asset additions included in accounts payable and accrued expenses | ​ | $ | 597 | ​ | $ | 910
Cash paid in connection with operating lease liabilities | ​ | ​ | 8,918 | ​ | ​ | 7,757
Offering costs included in accounts payable and accrued expenses | ​ | ​ | — | ​ | ​ | 158
Right-of-use assets obtained in exchange of operating lease obligations | ​ | ​ | 9,753 | ​ | ​ | —

​
The accompanying notes are an integral part of the condensed consolidated financial statements.

​

8

Table of Contents

Editas Medicine, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

​

1. Nature of Business

​

Editas Medicine, Inc. (the “Company”) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.

Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, a wholly-owned subsidiary of the Bristol Myers Squibb Company (“Juno Therapeutics”), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”), which was terminated in August 2020.

The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.

Liquidity

​

In May 2021, the Company entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). As of September 30, 2021, the Company has not sold any shares of its common stock under the ATM Facility.

​

In January 2021, the Company completed a public offering whereby it sold 3,500,000 shares of its common stock and received net proceeds of approximately $216.9 million. In February 2021, the underwriters in the public offering exercised their option to purchase an additional 525,000 shares, resulting in additional net proceeds to the Company of approximately $32.6 million.

​

The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities at September 30, 2021 and anticipated interest income will enable it to fund its operating expenses and capital expenditure requirements well into 2023. The Company had an accumulated deficit of $816.3 million at September 30, 2021, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

​

9

Table of Contents

2. Summary of Significant Accounting Policies

​

Unaudited Interim Financial Information

​

The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”).

​

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Editas Securities Corporation. All intercompany transactions and balances of the subsidiary have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended September 30, 2021 and 2020 are referred to as the third quarter of 2021 and 2020, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

​

Summary of Significant Accounting Policies

​

The Company’s significant accounting policies are described in Note 2, “Summary of significant accounting policies,” to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report.

​

​

​

3. Cash Equivalents and Marketable Securities

​

Cash equivalents and marketable securities consisted of the following at September 30, 2021 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Allowance | ​ | ​ | Gross | ​ | Gross | ​ | ​
​ | ​ | Amortized | ​ | for Credit | ​ | ​ | Unrealized | ​ | Unrealized | ​ | Fair
September 30, 2021 | ​ | Cost | ​ | Losses | ​ | ​ | Gains | ​ | Losses | ​ | Value
Cash equivalents and marketable securities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 259,884 | ​ | $ | — | ​ | ​ | $ | — | ​ | $ | — | ​ | $ | 259,884
U.S. Treasuries | ​ | ​ | 109,060 | ​ | ​ | — | ​ | ​ | ​ | 4 | ​ | ​ | (15) | ​ | ​ | 109,049
Government agency securities | ​ | ​ | 118,708 | ​ | ​ | — | ​ | ​ | ​ | 1 | ​ | ​ | (17) | ​ | ​ | 118,692
Commercial Paper | ​ | ​ | 101,167 | ​ | ​ | — | ​ | ​ | ​ | 3 | ​ | ​ | (6) | ​ | ​ | 101,164
Corporate notes/bonds | ​ | ​ | 68,284 | ​ | ​ | — | ​ | ​ | ​ | 2 | ​ | ​ | (36) | ​ | ​ | 68,250
Total | ​ | $ | 657,103 | ​ | $ | — | ​ | ​ | $ | 10 | ​ | $ | (74) | ​ | $ | 657,039

​

10

Table of Contents

Cash equivalents and marketable securities consisted of the following at December 31, 2020 (in thousands):
​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Allowance | ​ | ​ | Gross | ​ | Gross | ​ | ​
​ | ​ | Amortized | ​ | for Credit | ​ | ​ | Unrealized | ​ | Unrealized | ​ | Fair
December 31, 2020 | ​ | Cost | ​ | Losses | ​ | ​ | Gains | ​ | Losses | ​ | Value
Cash equivalents and marketable securities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 139,682 | ​ | $ | — | ​ | ​ | $ | — | ​ | $ | — | ​ | $ | 139,682
U.S. Treasuries | ​ | ​ | 180,376 | ​ | ​ | — | ​ | ​ | ​ | 8 | ​ | ​ | (11) | ​ | ​ | 180,373
Government agency securities | ​ | ​ | 107,665 | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ | (20) | ​ | ​ | 107,645
Commercial paper | ​ | ​ | 41,912 | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ | (8) | ​ | ​ | 41,904
Corporate notes/bonds | ​ | ​ | 42,185 | ​ | ​ | — | ​ | ​ | ​ | 10 | ​ | ​ | (25) | ​ | ​ | 42,170
Total | ​ | $ | 511,820 | ​ | $ | — | ​ | ​ | $ | 18 | ​ | $ | (64) | ​ | $ | 511,774

​

As of September 30, 2021, the Company did not hold any marketable securities that had been in an unrealized loss position for more than twelve months. Furthermore, the Company has determined that there were no material changes in the credit risk of the debt securities. As of September 30, 2021, the Company holds 29 securities with an aggregate fair value of $99.2 million that had remaining maturities between one and two years.

​

There were no realized gains or losses on available-for-sale securities during the nine months ended September 30, 2021 or 2020.

​

4. Fair Value Measurements

​

Assets measured at fair value on a recurring basis as of September 30, 2021 were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Quoted Prices |  | Significant |  | ​ | ​
​ | ​ | ​ | ​ | ​ | in Active | ​ | Other | ​ | Significant
​ | ​ | ​ | ​ | ​ | Markets for | ​ | Observable | ​ | Unobservable
​ | ​ | September 30, | ​ | Identical Assets | ​ | Inputs | ​ | Inputs
Financial Assets | ​ | 2021 | ​ | (Level 1) | ​ | (Level 2) | ​ | (Level 3)
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 259,884 | ​ | $ | 259,884 | ​ | $ | — | ​ | $ | —
Marketable securities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. Treasuries | ​ | ​ | 109,049 | ​ | ​ | 109,049 | ​ | ​ | — | ​ | ​ | —
Government agency securities | ​ | ​ | 118,692 | ​ | ​ | — | ​ | ​ | 118,692 | ​ | ​ | —
Commercial paper | ​ | ​ | 101,164 | ​ | ​ | — | ​ | ​ | 101,164 | ​ | ​ | —
Corporate notes/bonds | ​ | ​ | 68,250 | ​ | ​ | — | ​ | ​ | 68,250 | ​ | ​ | —
Restricted cash and other non-current assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | ​ | 3,877 | ​ | ​ | 3,877 | ​ | ​ | — | ​ | ​ | —
Total financial assets | ​ | $ | 660,916 | ​ | $ | 372,810 | ​ | $ | 288,106 | ​ | $ | —

​

11

Table of Contents

Assets measured at fair value on a recurring basis as of December 31, 2020 were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Quoted Prices |  | Significant |  | ​ | ​
​ | ​ | ​ | ​ | ​ | in Active | ​ | Other | ​ | Significant
​ | ​ | ​ | ​ | ​ | Markets for | ​ | Observable | ​ | Unobservable
​ | ​ | December 31, | ​ | Identical Assets | ​ | Inputs | ​ | Inputs
Financial Assets | ​ | 2020 | ​ | (Level 1) | ​ | (Level 2) | ​ | (Level 3)
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 139,682 | ​ | $ | 139,682 | ​ | $ | — | ​ | $ | —
Marketable securities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. Treasuries | ​ | ​ | 180,373 | ​ | ​ | 180,373 | ​ | ​ | — | ​ | ​ | —
Government agency securities | ​ | ​ | 107,645 | ​ | ​ | — | ​ | ​ | 107,645 | ​ | ​ | —
Commercial paper | ​ | ​ | 41,904 | ​ | ​ | — | ​ | ​ | 41,904 | ​ | ​ | —
Corporate bonds | ​ | ​ | 42,170 | ​ | ​ | — | ​ | ​ | 42,170 | ​ | ​ | —
Restricted cash and other non-current assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | ​ | 3,877 | ​ | ​ | 3,877 | ​ | ​ | — | ​ | ​ | —
Total financial assets | ​ | $ | 515,651 | ​ | $ | 323,932 | ​ | $ | 191,719 | ​ | $ | —

​

​

​

​

5. Accrued Expenses

​

Accrued expenses consisted of the following (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of
​ | ​ | September 30, | ​ | December 31,
​ |  | 2021 |  | 2020
Employee related expenses | ​ | $ | 9,639 | ​ | $ | 5,323
External research and development expenses | ​ | ​ | 2,381 | ​ |  | 12,820
Intellectual property and patent related fees | ​ | ​ | 1,606 | ​ | ​ | 4,240
Professional service expenses | ​ | ​ | 640 | ​ | ​ | 533
Other expenses | ​ | ​ | 271 | ​ | ​ | 359
Sublicensing expenses | ​ | ​ | 38 | ​ | ​ | 771
Total accrued expenses | ​ | $ | 14,575 | ​ | $ | 24,046
​ | ​ | ​ | ​ | ​ | ​ | ​

​

12

Table of Contents

6. Property and Equipment, net

​

Property and equipment, net consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | As of
​ | ​ | September 30, | ​ | December 31,
​ |  | 2021 |  | 2020
Laboratory equipment | ​ | $ | 20,647 | ​ | $ | 18,433
Leasehold improvements | ​ | ​ | 5,427 | ​ | ​ | 4,967
Construction-in-progress | ​ |  | 2,360 | ​ |  | 500
Computer equipment | ​ | ​ | 858 | ​ | ​ | 858
Furniture and office equipment | ​ | ​ | 264 | ​ | ​ | 239
Software | ​ |  | 118 | ​ |  | 118
Total property and equipment | ​ |  | 29,674 | ​ |  | 25,115
Less: accumulated depreciation | ​ |  | (14,043) | ​ |  | (11,095)
Property and equipment, net | ​ | $ | 15,631 | ​ | $ | 14,020

​

​

7. Commitments and Contingencies

​

The Company is a party to a number of license agreements under which the Company licenses patents, patent applications and other intellectual property from third parties. As such, the Company is obligated to pay licensors for various costs including upfront licenses fees, annual license fees, certain licensor expense reimbursements, success payments, research funding payments, and milestones triggerable upon certain development, regulatory, and commercial events as well as royalties on future products. These contracts are generally cancellable, with notice, at the Company’s option and do not have significant cancellation penalties. The terms and conditions as well as the accounting analysis for the Company’s significant commitments and contingencies are described in Note 8, “Commitments and Contingencies” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.

​

Licensor Expense Reimbursement

​

The Company is obligated to reimburse The Broad Institute, Inc. (“Broad”) and the President and Fellows of Harvard College (“Harvard”) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the license agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. The Company incurred an aggregate of $1.8 million and $9.0 million in expense during the three and nine months ended September 30, 2021, respectively, for such reimbursement. The Company incurred an aggregate of $2.6 million and $9.3 million in expense during the three and nine months ended September 30, 2020, respectively, for such reimbursement.

​

8. Collaboration and Profit-Sharing Agreements

​

The Company has entered into multiple collaborations, out-licenses and strategic alliances with third parties that typically involve payments to or from the Company, including up-front payments, payments for research and development services, option payments, milestone payments and royalty payments to or from the Company. The terms and conditions as well as the accounting analysis for the Company’s significant collaborations, out-licenses and strategic alliances are described in Note 9, “Collaboration and Profit-Sharing Agreements” to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions, previously disclosed in the Annual Report.

​

​

​

13

Table of Contents

Collaboration Revenue

​

As of September 30, 2021, the Company’s contract liabilities were primarily related to the Company’s collaboration with Juno Therapeutics. The following table presents changes in the Company’s accounts receivable and contract liabilities for the nine months ended September 30, 2021 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the nine months ended September 30, 2021 | Balance at December 31, 2020 | ​ | Additions | ​ | Deductions | ​ | Balance at September 30, 2021
Accounts receivable | $ | 6,048 | ​ | $ | 390 | ​ | $ | (6,187) | ​ | $ | 251
Contract liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Deferred revenue | $ | 94,927 | ​ | $ | — | ​ | $ | (11,372) | ​ | $ | 83,555

​

During the three and nine months ended September 30, 2021, the Company recognized the following collaboration revenue (in thousands):

​ | ​ | ​ | ​ | ​ | ​
​ | Three Months Ended | ​ | Nine Months Ended
Revenue recognized in the period from: | September 30, 2021
Amounts included in deferred revenue at the beginning of the period | $ | 5,666 | ​ | $ | 11,372
Performance obligations satisfied in previous periods | $ | — | ​ | $ | —

​

​

9. Stock-based Compensation

​

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations was as follows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ | ​ | 2021 | ​ | 2020 | ​ | 2021 | ​ | 2020
Research and development | ​ | $ | 4,552 | ​ | $ | 2,938 | ​ | $ | 12,689 | ​ | $ | 8,668
General and administrative | ​ |  | 5,460 | ​ |  | 2,908 | ​ |  | 23,053 | ​ |  | 8,815
Total stock-based compensation expense | ​ | $ | 10,012 | ​ | $ | 5,846 | ​ | $ | 35,742 | ​ | $ | 17,483

​

Restricted Stock and Restricted Stock Unit Awards

​

The following is a summary of restricted stock and restricted stock unit awards activity for the nine months ended September 30, 2021:

​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted
​ | ​ | ​ | ​ | Average
​ | ​ | ​ | ​ | Grant Date
​ | ​ | ​ | ​ | Fair Value
​ | ​ | Shares | ​ | Per Share
Unvested restricted stock and restricted stock unit awards as of December 31, 2020 |  | 507,450 | ​ | $ | 27.35
Issued |  | 614,775 | ​ | $ | 48.12
Vested |  | (191,075) | ​ | $ | 31.08
Forfeited | ​ | (180,694) | ​ | $ | 38.70
Unvested restricted stock and restricted stock unit awards as of September 30, 2021 |  | 750,456 | ​ | $ | 41.33

​

The restricted stock and restricted stock units granted in the nine months ended September 30, 2021 include 226,747 units granted to certain employees that contain performance-based vesting provisions. The Company recognizes the fair value of the performance-based units through the expected achievement date if the performance-based vesting provisions are deemed probable.

​

As of September 30, 2021, total unrecognized compensation expense related to unvested restricted stock and restricted stock unit awards was $18.7 million, which the Company expects to recognize over a remaining weighted-average period of 2.1 years.

14

Table of Contents

​

Stock Options

​

The following is a summary of stock option activity for the nine months ended September 30, 2021:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted Average |  | Remaining |  | Aggregate Intrinsic
​ | ​ | Shares | ​ | Exercise Price | ​ | Contractual Life (years) | ​ | Value (in thousands)
Outstanding at December 31, 2020 |  | 3,912,257 | ​ | $ | 27.26 | ​ | 7.9 | ​ | $ | 167,640
Granted | ​ | 1,206,841 | ​ | $ | 45.58 | ​ | ​ | ​ | ​ | ​
Exercised | ​ | (1,218,120) | ​ | $ | 25.50 | ​ | ​ | ​ | ​ | ​
Cancelled | ​ | (817,563) | ​ | $ | 30.83 | ​ | ​ | ​ | ​ | ​
Outstanding at September 30, 2021 |  | 3,083,415 | ​ | $ | 34.18 | ​ | 7.8 | ​ | $ | 28,399
Exercisable at September 30, 2021 |  | 1,318,174 | ​ | $ | 28.58 | ​ | 7.0 | ​ | $ | 17,411

​

The stock options granted in the nine months ended September 30, 2021 include option grants to the Company’s Chief Executive Officer to purchase 196,637 and 341,978 shares of the Company’s common stock that contained market-based vesting provisions and performance-based vesting provisions, respectively. The Company recognizes the fair value of the market-based options over the earlier of the derived service period, valued using the Monte-Carlo simulation model, or when the market-based vesting conditions are met. The Company recognizes the fair value of the performance-based options through the expected achievement date if the performance-based vesting provisions are deemed probable.

​

As of September 30, 2021, total unrecognized compensation expense related to stock options was $33.3 million, which the Company expects to recognize over a remaining weighted-average period of 2.5 years.

​

10. Net (Loss) Income per Share

​

Basic net (loss) income per common share is calculated by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net (loss) income per share is computed by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic (loss) income per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted (loss) income per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ | ​ | 2021 | ​ | 2020 | ​ | 2021 | ​ | 2020
Net (loss) income | ​ | $ | (39,082) | ​ | $ | 7,819 | ​ | $ | (151,066) | ​ | $ | (53,477)
​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average common shares outstanding, basic | ​ |  | 68,219,742 | ​ | ​ | 62,144,118 | ​ | ​ | 67,371,246 | ​ | ​ | 57,377,581
Dilutive effect of outstanding stock options | ​ | ​ | — | ​ | ​ | 414,640 | ​ | ​ | — | ​ | ​ | —
Dilutive effect of unvested restricted stock and restricted stock unit awards | ​ |  | — | ​ |  | 138,415 | ​ |  | — | ​ |  | —
Weighted average common shares outstanding, diluted | ​ | ​ | 68,219,742 | ​ | ​ | 62,697,173 | ​ | ​ | 67,371,246 | ​ | ​ | 57,377,581
​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net (loss) income per share, basic | ​ | $ | (0.57) | ​ | $ | 0.13 | ​ | $ | (2.24) | ​ | $ | (0.93)
Net (loss) income per share, diluted | ​ | $ | (0.57) | ​ | $ | 0.12 | ​ | $ | (2.24) | ​ | $ | (0.93)

15

Table of Contents

​

​

The following common stock equivalents were excluded from the calculation of diluted net (loss) income per share allocable to common stockholders because their inclusion would have been anti-dilutive:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended | ​ | Nine months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2021 | ​ | 2020 | ​ | 2021 |  | 2020
Unvested restricted stock and restricted stock unit awards |  | 750,456 | ​ | 371,463 | ​ | 750,456 |  | 509,878
Outstanding stock options |  | 3,083,415 | ​ | 3,626,151 | ​ | 3,083,415 |  | 4,040,791
Total |  | 3,833,871 | ​ | 3,997,614 | ​ | 3,833,871 |  | 4,550,669

​

​

16

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

​

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (“SEC”) on February 26, 2021 (the “Annual Report”).

​

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements addressing our future operating performance and clinical development and regulatory timelines that we expect or anticipate will occur in the future, are forward-looking statements. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements, including uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of our product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail in our Annual Report under the captions “Risk Factor Summary” and “Risk Factors,” as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

​

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

​

Overview

​

We are a leading, clinical stage genome editing company dedicated to developing potentially transformative gene-editing medicines to treat a broad range of serious diseases. We have developed a proprietary gene-editing platform based on CRISPR technology and we continue to expand its capabilities. Our product development strategy is to target diseases of high unmet need where we aim to make differentiated, transformational medicines using our gene-editing platform. We are advancing in vivo gene-editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, ex vivo gene-edited cell medicines, in which cells collected from a patient are edited with our technology and then administered back to that same patient, and cellular therapy medicines, in which we use our technology to edit induced human pluripotent stem cells that are subsequently differentiated into effector cells, such as natural killer cells, to develop medicines that can be administered to a patient. While our discovery efforts have ranged across several diseases and therapeutic areas, the areas where our programs are more mature are in our in vivo gene-editing medicines to treat ocular diseases, our ex vivo gene-edited cell medicines to treat hemoglobinopathies, and our cellular therapy medicines to treat cancer.

In ocular diseases, our most advanced program is designed to address a specific genetic form of retinal degeneration called Leber congenital amaurosis 10 (“LCA10”), a CEP290-related retinal degenerative disorder for which we are not aware of any available therapies and only one other potential treatment is in clinical trials in the United States and Europe. In mid-2019, we initiated our Phase 1/2 BRILLIANCE clinical trial of EDIT-101, an experimental gene-editing medicine to treat LCA10. The BRILLIANCE trial is designed to assess the safety, tolerability, and efficacy of EDIT-101. We plan to enroll approximately 18 patients in the United States and Europe in up to five cohorts. We

17

Table of Contents

have completed dosing of the first two cohorts, the adult low-dose and mid-dose cohorts, and in the third quarter of 2021 began dosing in the adult high-dose cohort. We also are currently enrolling patients in the first of two planned pediatric cohorts. We remain on track to complete dosing of both the adult high-dose cohort and the pediatric mid-dose cohort in the first half of 2022.

In September 2021, we announced initial clinical data, consisting of preliminary patient safety and efficacy assessments, from the ongoing BRILLIANCE trial. The initial data related to the first six patients dosed in the trial: two in the adult low-dose cohort and four in the adult mid-dose cohort. Patients received a single administration of EDIT-101 via subretinal injection in one eye and are monitored every three months for the first year after dosing, and less frequently in the following two years. No dose-limiting toxicities, which are defined as vision-threatening toxicities or severe non-ocular adverse events that occur before or at the week four visit and assessed by the investigator as being related to EDIT-101 and not the administration procedure, or serious adverse events were reported in the first six adult patients treated. Efficacy was assessed based on available data from five subjects treated in the low-dose and mid-dose cohorts who had at least three months of post-treatment follow-up, focusing on those measures demonstrated to be consistent and reproducible in subjects with CEP290-related retinal degeneration, including best corrected visual acuity (“BCVA”), full-field light sensitivity threshold (“FST”) testing and ability to navigate standardized navigation courses, or Visual Function Navigation (“VNC”). Two of three subjects in the mid-dose cohort followed for up to six months showed early efficacy signals providing clinical evidence of gene editing and suggesting potential clinical benefits, including improvements in BCVA, FST, and/or mobility navigation.

For our ex vivo gene-edited cell medicines, our lead program is EDIT-301, an experimental medicine to treat sickle cell disease, a severe inherited blood disease that causes premature death, and beta-thalassemia, another inherited blood disorder characterized by severe anemia. In December 2020, we submitted an investigational new drug application (“IND”) to the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 1/2 clinical trial of EDIT-301, which we refer to as our RUBY trial, for the treatment of sickle cell disease. In January 2021, the FDA cleared the start of enrollment and dosing of patients in the first phase of the trial (which is designed to validate the safety and beneficial effects of the cell editing process). The RUBY trial is currently enrolling study participants, and we expect to begin dosing in the trial in the first half of 2022. Prior to initiating a registrational trial, we will be required to develop a potency assay to ensure that the characteristics of the product released are as expected and confirmed by clinical data collected in the first patients treated, in response to an FDA partial clinical hold. We remain on track to submit an IND for EDIT-301 for the treatment of transfusion-dependent beta-thalassemia by the end of 2021.

In cellular therapy medicines, we continue to develop our capabilities to generate cells from induced human pluripotent stem cells to develop engineered cell medicines to treat cancer. We are also advancing alpha-beta T cell experimental medicines in collaboration with Bristol-Myers Squibb Company (“BMS”). In May 2015, we entered into a collaboration with Juno Therapeutics, Inc., a wholly-owned subsidiary of BMS (“Juno Therapeutics”), to develop novel engineered alpha-beta T cell therapies for cancer and autoimmune diseases, which was amended and restated in each of May 2018 and November 2019, at which time we also entered into a related license agreement with Juno Therapeutics, which we collectively refer to as our collaboration with them.

In March 2017, we entered into a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”) to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. We received an aggregate of $130.0 million in payments under this agreement, which consisted of the initial upfront payment, an option exercise payment, and a milestone payment. We and Allergan subsequently entered into a co-development and commercialization agreement under which we agreed to co-develop and equally split profits and losses for EDIT-101 in the United States. In August 2020, we and Allergan terminated the strategic alliance and option agreement and the co-development and commercialization agreement, and we assumed full rights to EDIT-101 and responsibility for conducting the clinical trial. In connection with such termination, we and Allergan entered into a termination agreement, pursuant to which we made a one-time aggregate payment of $20.0 million to Allergan.

Since our inception in September 2013, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, assembling our core capabilities in gene editing, seeking to identify potential product candidates, and undertaking preclinical studies. Except for EDIT-101

18

Table of Contents

and EDIT-301, all of our research programs are still in the preclinical or research stage of development and the risk of failure of all of our research programs is high. We have not generated any revenue from product sales. We have primarily financed our operations through various equity financings and payments received under our research collaboration with Juno Therapeutics and our strategic alliance with Allergan.

Since inception, we have incurred significant operating losses. Our net losses were $151.1 million and $53.5 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, we had an accumulated deficit of $816.3 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and from year to year. We anticipate that our expenses will increase substantially as we continue our current research programs and our preclinical development activities; progress the clinical development of EDIT-101 for the treatment of LCA10 and EDIT-301 for the treatment of sickle cell disease; seek to identify additional research programs and additional product candidates; initiate preclinical testing and clinical trials for other product candidates we identify and develop, including EDIT-301 for the treatment of transfusion-dependent beta-thalassemia; maintain, expand, and protect our intellectual property portfolio, including reimbursing our licensors for such expenses related to the intellectual property that we in-license from such licensors; further develop our genome editing platform; hire additional clinical, quality control, and scientific personnel; and incur costs associated with operating as a public company. We do not expect to be profitable for the year ending December 31, 2021 or the foreseeable future.

Although we did not experience any significant impact on our financial condition, results of operations or liquidity due to the ongoing COVID-19 pandemic during the nine months ended September 30, 2021, the pandemic continues to be dynamic and near-term risks to our business remain. Vaccines are being distributed and administered, but utilization of the vaccines has been varied and new variants of the virus have emerged, and may continue to emerge, that are more contagious, which can result in increased infection rates and re-imposed governmental restrictions to reduce the spread of COVID-19. As a result, the ultimate impact of the COVID-19 pandemic continues to be highly uncertain and we do not yet know the full extent of potential delays or impacts on our business, our ability to continue to raise additional capital, the EDIT-101 or EDIT-301 clinical trials, ongoing preclinical activities, or the global economy as a whole. In March 2020, we implemented a work from home policy, and restricted on-site activities at our facilities in Massachusetts and Colorado to certain manufacturing, laboratory and related support activities in light of the COVID-19 pandemic. Under our return to onsite work plans, we gradually resumed manufacturing, laboratory and related support activities at our facilities in Massachusetts and Colorado, and fully reopened our facilities in the third quarter of 2021 using a hybrid work model. We will continue to monitor and respond to the changing conditions created by the pandemic, with focus on prioritizing the health and safety of our employees and maintaining safe and reliable operations of our facilities.

Financial Operations Overview

​

Revenue

​

To date, we have not generated any revenue from product sales and we do not expect to generate any revenue from product sales for the foreseeable future. In connection with our collaboration with Juno Therapeutics, we have received an aggregate of $126.5 million in payments, which have primarily consisted of the initial upfront and amendment payments, development milestone payments, research funding support and certain opt-in fees. We no longer receive research funding support. As of September 30, 2021, we recorded $79.3 million of deferred revenue in relation to our collaboration with Juno Therapeutics, of which $56.7 million is classified as long-term on our condensed consolidated balance sheet. During the nine months ended September 30, 2021, we recognized $11.3 million of previously deferred revenue related to our collaboration with Juno Therapeutics. Under this collaboration, we will recognize revenue upon delivery of option packages to Juno Therapeutics or upon receipt of development milestone payments. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year as a result of the timing of when we deliver such option packages or receive such milestone payments.

For additional information about our revenue recognition policy related to the Juno Therapeutics collaboration, see “—Critical Accounting Policies and Estimates—Revenue Recognition” included in our Annual Report.

19

Table of Contents

For the foreseeable future we expect substantially all of our revenue will be generated from our collaboration with Juno Therapeutics, and any other collaborations or agreements we may enter into.

Expenses

​

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research and development activities, including our drug discovery efforts and preclinical studies and clinical trials under our research programs, which include:

| ● | employee-related expenses including salaries, benefits, and stock-based compensation expense;

| ● | costs of funding research performed by third parties that conduct research and development and preclinical and clinical activities on our behalf;

| ● | costs of purchasing lab supplies and non-capital equipment used in our preclinical activities and in manufacturing preclinical study materials;

| ● | consultant fees;

| ● | facility costs, including rent, depreciation, and maintenance expenses; and

| ● | fees for acquiring and maintaining licenses under our third-party licensing agreements, including any sublicensing or success payments made to our licensors.

Research and development costs are expensed as incurred. At this time, we cannot reasonably estimate or know

the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of any product candidates we may identify and develop. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty of:

​

| ● | successful completion of preclinical studies, IND-enabling studies and natural history studies;

| ● | successful enrollment in, and completion of, clinical trials;

| ● | receipt of marketing approvals from applicable regulatory authorities;

| ● | establishing clinical, commercial manufacturing capabilities or making arrangements with third-party manufacturers;

| ● | obtaining and maintaining patent and trade secret protection and non-patent exclusivity;

| ● | launching commercial sales of a product, if and when approved, whether alone or in collaboration with others;

| ● | acceptance of a product, if and when approved, by patients, the medical community, and third-party payors;

| ● | effectively competing with other therapies and treatment options;

| ● | a continued acceptable safety profile following approval;

| ● | enforcing and defending intellectual property and proprietary rights and claims; and

20

Table of Contents

| ● | achieving desirable medicinal properties for the intended indications.

A change in the outcome of any of these variables with respect to the development of any product candidates we develop would significantly change the costs, timing, and viability associated with the development of that product candidate.

​

Research and development activities are central to our business model. We expect research and development costs to increase significantly for the foreseeable future as our development programs progress, including as we continue to progress the clinical development of EDIT-101 and EDIT-301 as well as supporting preclinical studies for our other research programs.

​

General and Administrative Expenses

​

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in executive, finance, investor relations, business development, legal, corporate affairs, information technology, facilities and human resource functions. Other significant costs include corporate facility costs not otherwise included in research and development expenses, legal fees related to intellectual property and corporate matters, and fees for accounting and consulting services.

We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities and potential commercialization of any product candidates we identify and develop. These increases will include increased costs related to the hiring of additional personnel and fees to outside consultants. We also anticipate increased expenses related to reimbursement of third-party patent-related expenses and expenses associated with operating as a public company, including costs for audit, legal, regulatory, and tax-related services, director and officer insurance premiums, and investor relations costs. With respect to reimbursement of third-party intellectual property-related expenses specifically, given the ongoing nature of the opposition and interference proceedings involving the patents licensed to us under our license agreements with The Broad Institute, Inc. (“Broad”) and the President and Fellows of Harvard College (“Harvard”), we anticipate general and administrative expenses will continue to be significant.

Other Income (Expense), Net

​

For the nine months ended September 30, 2021, other income (expense), net consisted primarily of interest income and accretion of discounts associated with other marketable securities.

​

For the nine months ended September 30, 2020, other income (expense), net consisted primarily of changes in the fair value of equity securities, interest income and accretion of discounts associated with other marketable securities.

​

Critical Accounting Policies and Estimates

​

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.

​

There have been no material changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report.

​

21

Table of Contents

​

Results of Operations

​

Comparison of the Three Months ended September 30, 2021 and 2020

​

The following table summarizes our results of operations for the three months ended September 30, 2021 and 2020, together with the changes in those items in dollars (in thousands) and the respective percentages of change:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | ​ | ​ | ​
​ |  | 2021 |  | 2020 |  | Dollar Change |  | Percentage Change
Collaboration and other research and development revenues | ​ | $ | 6,197 | ​ | $ | 62,841 | ​ | $ | (56,644) | ​ | (90) | %
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ |  | 29,265 | ​ |  | 33,916 | ​ |  | (4,651) | ​ | (14) | %
General and administrative | ​ |  | 16,185 | ​ |  | 19,936 | ​ |  | (3,751) | ​ | (19) | %
Total operating expenses | ​ |  | 45,450 | ​ |  | 53,852 | ​ |  | (8,402) | ​ | (16) | %
Other income, net: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other income (expense), net | ​ |  | 19 | ​ |  | (1,396) | ​ |  | 1,415 | ​ | n/m | ​
Interest income, net | ​ |  | 152 | ​ |  | 226 | ​ |  | (74) | ​ | (33) | %
Total other income (expense), net | ​ |  | 171 | ​ |  | (1,170) | ​ |  | 1,341 | ​ | n/m | ​
Net (loss) income | ​ | $ | (39,082) | ​ | $ | 7,819 | ​ | $ | (46,901) | ​ | n/m | ​

​

For our results of operations, we have included the respective percentage of changes, unless greater than 100% or less than (100)%, in which case we have denoted such changes as not meaningful (n/m).

Collaboration and other research and development revenues

​

Collaboration and other research and development revenues decreased by $56.6 million, to $6.2 million for the three months ended September 30, 2021, compared to $62.8 million for three months ended September 30, 2020. This decrease was primarily attributable to the termination of our strategic alliance with Allergan during the third quarter of 2020 in which we recognized $59.9 million of previously deferred revenue, for which there was no similar revenue recognized during the third quarter of 2021.

​

Research and development expenses

​

Research and development expenses decreased by $4.7 million, to $29.2 million for the three months ended September 30, 2021, compared to $33.9 million for the three months ended September 30, 2020. The following table summarizes our research and development expenses for the three months ended September 30, 2021 and 2020, together with the changes in those items in dollars (in thousands) and the respective percentages of change:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | ​
​ |  | 2021 |  | 2020 |  | Dollar Change | ​ | Percentage Change
External research and development expenses | ​ | $ | 10,777 | ​ | $ | 18,204 | ​ | $ | (7,427) | ​ | (41) | %
Employee related expenses | ​ | ​ | 10,177 | ​ | ​ | 8,072 | ​ | ​ | 2,105 | ​ | 26 | %
Stock-based compensation expenses | ​ | ​ | 4,552 | ​ | ​ | 2,938 | ​ |  | 1,614 | ​ | 55 | %
Facility expenses | ​ |  | 4,085 | ​ | ​ | 3,617 | ​ |  | 468 | ​ | 13 | %
Sublicense and license fees | ​ | ​ | 1,045 | ​ | ​ | 192 | ​ |  | 853 | ​ | n/m | ​
Other expenses | ​ | ​ | (1,371) | ​ | ​ | 893 | ​ | ​ | (2,264) | ​ | n/m | ​
Total research and development expenses | ​ | $ | 29,265 | ​ | $ | 33,916 | ​ | $ | (4,651) | ​ | (14) | %

​

22

Table of Contents

The decrease in research and development expenses for the three months ended September 30, 2021 compared to the three months ended September 30, 2020 was primarily attributable to:

​

| ● | approximately $7.4 million in decreased external research and development expenses related primarily to a one-time in-process research and development expense of $5.0 million for re-acquiring the rights to EDIT-101 from Allergan in the third quarter of 2020 for which there was no similar expense in the third quarter of 2021; and

​

| ● | approximately $2.3 million in decreased expenses related to a COVID-19 employee retention tax credit recognized in the third quarter 2021 which is included in other expenses in the table above.

​

These decreases were partially offset by:

​

| ● | approximately $2.1 million in increased employee related expenses primarily due to an increase in the size of our workforce, including the expansion of our research and development organization;

​

| ● | approximately $1.6 million in increased stock-based compensation expenses primarily due to an increase in restricted stock units granted to employees;

​

| ● | approximately $0.9 million in increased sublicense and license fees; and

​

| ● | approximately $0.5 million in increased facility related expenses.

​

​

General and administrative expenses

​

General and administrative expenses decreased by $3.7 million, to $16.2 million for the three months ended September 30, 2021, compared to $19.9 million for the three months ended September 30, 2020. The following table summarizes our general and administrative expenses for the three months ended September 30, 2021 and 2020, together with the changes in those items in dollars (in thousands) and the respective percentages of change:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | ​
​ |  | 2021 |  | 2020 |  | Dollar Change | ​ | Percentage Change
Stock-based compensation expenses | ​ | $ | 5,460 | ​ | $ | 2,908 | ​ | $ | 2,552 | ​ | 88 | %
Employee related expenses | ​ | ​ | 4,163 | ​ | ​ | 4,164 | ​ | ​ | (1) | ​ | (0) | %
Intellectual property and patent related fees | ​ | ​ | 3,378 | ​ | ​ | 4,446 | ​ |  | (1,068) | ​ | (24) | %
Other expenses | ​ |  | 1,641 | ​ |  | 2,104 | ​ |  | (463) | ​ | (22) | %
Professional service expenses | ​ |  | 1,543 | ​ |  | 6,314 | ​ |  | (4,771) | ​ | (76) | %
Total general and administrative expenses | ​ | $ | 16,185 | ​ | $ | 19,936 | ​ | $ | (3,751) | ​ | (19) | %

​

The decrease in general and administrative expenses for the three months ended September 30, 2021 compared to the three months ended September 30, 2020 was primarily attributable to:

​

| ● | $4.8 million in decreased professional service expenses primarily due to additional professional service expenses incurred in the third quarter of 2020 in connection with the termination of the Allergan agreement for which there were no similar activities in the third quarter of 2021;

​

| ● | approximately $1.1 million in decreased intellectual property and patent related fees; and

​

| ● | approximately $0.5 million in decreased other expenses related to a COVID-19 employee retention tax credit recognized in the third quarter of 2021.

​

These decreases were partially offset by approximately $2.6 million in increased stock-based compensation

23

Table of Contents

expenses which were primarily a result of market-based and performance-based awards that were granted to our Chief Executive Officer and certain other employees in 2021.

​

​

Other income (expense), net

​

For the three months ended September 30, 2021, other income, net was $0.2 million, which was primarily attributable to interest income, partially offset by accretion of discounts associated with other marketable securities.

​

For the three months ended September 30, 2020, other expense, net was $1.2 million, which was primarily attributable to the unrealized losses related to corporate equity securities, partially offset by interest income.

​

Comparison of the Nine Months ended September 30, 2021 and 2020

​

The following table summarizes our results of operations for the nine months ended September 30, 2021 and 2020, together with the changes in those items in dollars (in thousands) and the respective percentages of change:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2021 |  | 2020 |  | Dollar Change |  | Percentage Change
Collaboration and other research and development revenues | ​ | $ | 13,075 | ​ | $ | 79,313 | ​ | $ | (66,238) | ​ | (84) | %
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ |  | 104,954 | ​ |  | 96,492 | ​ |  | 8,462 | ​ | 9 | %
General and administrative | ​ |  | 59,657 | ​ |  | 51,789 | ​ |  | 7,868 | ​ | 15 | %
Total operating expenses | ​ |  | 164,611 | ​ |  | 148,281 | ​ |  | 16,330 | ​ | 11 | %
Other income, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other income, net | ​ |  | 38 | ​ |  | 13,114 | ​ |  | (13,076) | ​ | (100) | %
Interest income, net | ​ |  | 432 | ​ |  | 2,377 | ​ |  | (1,945) | ​ | (82) | %
Total other income, net | ​ |  | 470 | ​ |  | 15,491 | ​ |  | (15,021) | ​ | (97) | %
Net loss | ​ | $ | (151,066) | ​ | $ | (53,477) | ​ | $ | (97,589) | ​ | n/m | ​

​

Collaboration and other research and development revenues

​

Collaboration and other research and development revenues decreased by $66.2 million, to $13.1 million for the nine months ended September 30, 2021, compared to $79.3 million for the nine months ended September 30, 2020. This decrease was primarily attributable to the recognition of $63.2 million of previously deferred revenue as a result of the termination of our strategic alliance with Allergan in 2020 as well as to $7.6 million in revenue recognized pursuant to an out-license agreement we entered into during the second quarter 2020, for which there was no similar revenue recognized during 2021. This decrease was partially offset by $12.3 million in revenue recognized pursuant to our research collaboration with Juno Therapeutics during the nine months ended September 30, 2021, for which there was no similar revenue recognized in 2020.

​

​

Research and development expenses

​

Research and development expenses increased by $8.5 million, to $105.0 million for the nine months ended September 30, 2021, compared to $96.5 million for the nine months ended September 30, 2020. The following table summarizes our research and development expenses for the nine months ended September 30, 2021 and 2020, together with the changes in those items in dollars (in thousands) and the respective percentages of change:

​

24

Table of Contents

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended | ​ | ​ | ​ | ​ | ​ |
​ | ​ | September 30, | ​ | ​ | ​ | ​ | ​ |
​ | ​ | 2021 |  | 2020 |  | Dollar Change | ​ | Percentage Change
External research and development expenses | ​ | $ | 38,290 | ​ | $ | 46,162 | ​ | $ | (7,872) | ​ | (17) | %
Employee related expenses | ​ | ​ | 29,926 | ​ | ​ | 24,589 | ​ | ​ | 5,337 | ​ | 22 | %
Stock-based compensation expenses | ​ |  | 12,689 | ​ |  | 8,668 | ​ | ​ | 4,021 | ​ | 46 | %
Facility expenses | ​ | ​ | 12,042 | ​ | ​ | 9,909 | ​ |  | 2,133 | ​ | 22 | %
Sublicense and license fees | ​ | ​ | 10,673 | ​ | ​ | 4,132 | ​ | ​ | 6,541 | ​ | n/m | ​
Other expenses | ​ | ​ | 1,334 | ​ |  | 3,032 | ​ |  | (1,698) | ​ | (56) | %
Total research and development expenses | ​ | $ | 104,954 | ​ | $ | 96,492 | ​ | $ | 8,462 | ​ | 9 | %

​

The increase in research and development expenses for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020 was primarily attributable to:

​

| ● | approximately $6.5 million in increased sublicense and license fees primarily related to the triggering of success payments under certain of our license agreements upon the achievement of market capitalization-based milestones in the first quarter of 2021;

​

| ● | approximately $5.4 million in increased employee related expenses primarily due to an increase in the size of our workforce, including the expansion of our research and development organization;

​

| ● | approximately $4.0 million in increased stock-based compensation expenses primarily due to expense recognized in relation an increase in restricted stock units granted to employees; and

​

| ● | approximately $2.1 million in increased facility related expenses primarily related to increased lab and manufacturing space;

​

These increases were partially offset by:

​

| ● | approximately $7.9 million in decreased external research and development expenses related to expenses incurred in the nine months ended September 30, 2020 under our profit-sharing arrangement with Allergan, including a one-time in-process research and development expense of $5.0 million for re-acquiring the rights to EDIT-101 from Allergan in the third quarter of 2020, as well as a decrease in expenses incurred related to an in-license arrangement that we entered into during the first quarter 2020 for which there was no similar expense in 2021; and

​

| ● | approximately $1.7 million in decreased expenses related to a COVID-19 employee retention tax credit recognized in the nine months ended September 30, 2021, which is included in other expenses in the table above, offset by increased research and development related information technology expenses incurred during the nine months ended September 30, 2021.

​

General and administrative expenses

​

General and administrative expenses increased by $7.9 million, to $59.7 million for the nine months ended September 30, 2021, compared to $51.8 million for the nine months ended September 30, 2020. The following table summarizes our general and administrative expenses for the nine months ended September 30, 2021 and 2020, together with the changes in those items in dollars (in thousands) and the respective percentages of change:

​

25

Table of Contents

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended | ​ | ​ | ​ | ​ | ​ |
​ | ​ | September 30, | ​ | ​ | ​ | ​ | ​ |
​ | ​ | 2021 |  | 2020 |  | Dollar Change | ​ | Percentage Change
Stock-based compensation expenses | ​ | $ | 23,053 | ​ | $ | 8,815 | ​ | $ | 14,238 | ​ | n/m | ​
Intellectual property and patent related fees | ​ | ​ | 13,247 | ​ | ​ | 13,457 | ​ | ​ | (210) | ​ | (2) | %
Employee related expenses | ​ |  | 13,228 | ​ | ​ | 12,616 | ​ |  | 612 |  | 5 | %
Other expenses | ​ |  | 5,894 | ​ |  | 6,098 | ​ |  | (204) |  | (3) | %
Professional service expenses | ​ |  | 4,235 | ​ |  | 10,803 | ​ |  | (6,568) |  | (61) | %
Total general and administrative expenses | ​ | $ | 59,657 | ​ | $ | 51,789 | ​ | $ | 7,868 |  | 15 | %

​

The increase in general and administrative expenses for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020 was primarily attributable to:

​

| ● | approximately $14.2 million in increased stock-based compensation expenses related to the acceleration of vesting of certain equity awards held by our former Chief Executive Officer in connection with her separation from our company in February 2021, as well as stock-based compensation expenses as a result of market-based and performance-based awards that were granted to our new Chief Executive Officer and certain other employees in 2021; and

​

| ● | approximately $0.6 million in increased employee related expenses.

​

These increases were partially offset by:

​

| ● | approximately $6.6 million in decreased professional service expenses primarily due to additional professional service expenses incurred in the third quarter of 2020 in connection with the termination of the Allergan agreement for which there were no similar activities in 2021;

​

| ● | approximately $0.2 million in decreased intellectual property and patent related fees; and

​

| ● | approximately $0.2 million in decreased other expenses.

​

​

Other income, net

​

For the nine months ended September 30, 2021, other income, net was $0.5 million, which was primarily attributable to interest income, partially offset by accretion of discounts associated with other marketable securities.

​

For the nine months ended September 30, 2020, other income, net was income of $15.5 million, which was primarily attributable to the unrealized gains related to corporate equity securities, interest income and accretion of discounts associated with marketable securities.

​

26

Table of Contents

Liquidity and Capital Resources

​

Sources of Liquidity

​

In May 2021, we entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which we from time to time can issue and sell shares of our common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). As of September 30, 2021, we have not sold any shares of our common stock under the ATM Facility.

​

In January 2021, we completed a public offering whereby we sold 3,500,000 shares of our common stock and received net proceeds of approximately $216.9 million. In February 2021, the underwriters in the public offering exercised their option to purchase an additional 525,000 shares, resulting in additional net proceeds to us of approximately $32.6 million. As of September 30, 2021, we have raised an aggregate of $898.0 million in net proceeds through the sale of shares of our common stock in public offerings and at-the-market offerings. We also have funded our business from payments received under our research collaboration with Juno Therapeutics and our strategic alliance with Allergan, which was terminated in August 2020. As of September 30, 2021, we had cash, cash equivalents and marketable securities of $657.0 million.

​

In addition to our existing cash, cash equivalents and marketable securities, we are eligible to earn milestone and other payments under our collaboration agreement with Juno Therapeutics. Our ability to earn the milestone payments and the timing of earning these amounts are dependent upon the timing and outcome of our development, regulatory and commercial activities and, as such, are uncertain at this time. As of September 30, 2021, our right to contingent payments under our collaboration agreement with Juno Therapeutics is our only significant committed potential external source of funds.

Cash Flows

​

The following table provides information regarding our cash flows for the nine months ended September 30, 2021 and 2020 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended
​ | ​ | September 30,
​ | ​ | 2021 | ​ | 2020
Net cash (used in) provided by: | ​ | ​ | ​ | ​ | ​ | ​
Operating activities | ​ | $ | (129,221) | ​ | $ | (139,743)
Investing activities | ​ |  | (31,626) | ​ |  | (31,628)
Financing activities | ​ |  | 281,049 | ​ |  | 215,022
Net increase in cash, cash equivalents, and restricted cash | ​ | $ | 120,202 | ​ | $ | 43,651

​

Net Cash Used in Operating Activities

​

The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital.

​

Net cash used in operating activities was approximately $129.2 million for the nine months ended September 30, 2021, which primarily consisted of operating expenses that relate to our on-going preclinical and clinical activities, patent costs and license fees, and increased costs as a result of staffing needs due to our expanding operations. These expenses were partially offset by cash inflows from license fees received in the period.

​

Net cash used in operating activities was approximately $139.7 million for the nine months ended September 30, 2020, which primarily consisted of operating expenses that relate to our on-going preclinical and clinical activities, including a $17.5 million termination fee related to the termination of our agreements with Allergan, patent costs and license fees, and increased costs as a result of staffing needs due to our expanding operations. These expenses were partially offset by cash inflows from license fees received in the period.

27

Table of Contents

​

Net Cash Used in Investing Activities

​

Net cash used in investing activities was approximately $31.6 million for the nine months ended September 30, 2021, primarily related to costs to acquire marketable securities of $304.6 million and purchases of property and equipment of $5.1 million, partially offset by proceeds from maturities of marketable securities of $278.1 million.

​

Net cash used in investing activities was approximately $31.6 million for the nine months ended September 30, 2020, primarily related to costs used to acquire marketable securities of $300.4 million and costs to acquire property and equipment of $5.8 million, partially offset by proceeds from maturities of marketable securities of $274.5 million.

​

Net Cash Provided by Financing Activities

​

Net cash provided by financing activities was approximately $281.0 million for the nine months ended September 30, 2021 and consisted of $249.5 million in net proceeds received from the offering of our common stock and $31.1 million in proceeds received from exercises of options for our common stock.

​

Net cash provided by financing activities was approximately $215.0 million for the nine months ended September 30, 2020, and consisted of $203.8 million in net proceeds received from offering of common stock, of which $0.2 million of expenses related to the offering were unpaid at September 30, 2020, and $10.8 million in proceeds received from exercises of options for our common stock.

​

Funding Requirements

​

We expect our expenses to increase in connection with our ongoing activities, particularly as we progress the clinical development of EDIT-101 and EDIT-301; further advance our current research programs and our preclinical development activities; seek to identify product candidates and additional research programs; initiate preclinical testing and clinical trials for other product candidates we identify and develop, including EDIT-301 for the treatment of transfusion-dependent beta-thalassemia; maintain, expand, and protect our intellectual property portfolio, including reimbursing our licensors for expenses related to the intellectual property that we in-license from such licensors; hire additional clinical, quality control, and scientific personnel; and incur costs associated with operating as a public company. In addition, if we obtain marketing approval for any product candidate that we identify and develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, and distribution are not the responsibility of a collaborator. We do not expect to generate significant recurring revenue unless and until we obtain regulatory approval for and commercialize a product candidate. Furthermore, since 2016 we have incurred, and in future years we expect to continue to incur, significant costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

We expect that our existing cash, cash equivalents and marketable securities as of September 30, 2021 and anticipated interest income will enable us to fund our operating expenses and capital expenditure requirements well into 2023. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:

| ● | the scope, progress, results, and costs of drug discovery, preclinical development, laboratory testing, and clinical or natural history study trials for the product candidates we develop;

| ● | the costs of progressing the clinical development of EDIT-101 to treat LCA10;

| ● | the costs of progressing the clinical development of EDIT-301 to treat sickle cell disease;

| ● | the costs of IND-enabling studies and initiating any clinical trial for EDIT-301 to treat beta-thalassemia;

28

Table of Contents

| ● | the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims;

| ● | the costs, timing, and outcome of regulatory review of the product candidates we develop;

| ● | the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any product candidates for which we receive regulatory approval;

| ● | the success of our collaboration with Juno Therapeutics;

| ● | whether Juno Therapeutics exercises any of its options to extend the research program term and/or to additional research programs under our collaboration;

| ● | our ability to establish and maintain additional collaborations on favorable terms, if at all;

| ● | the extent to which we acquire or in-license other medicines and technologies;

| ● | the costs of reimbursing our licensors for the prosecution and maintenance of the patent rights in-licensed by us; and

| ● | the costs of operating as a public company.

Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, any product candidate that we identify and develop, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of genomic medicines that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Further, our ability to continue to raise additional capital may be adversely impacted by potential worsening global economic conditions and potential disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.

If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Contractual Obligations

​

The following table summarizes our significant contractual obligations as of payment due date by period at September 30, 2021 (in thousands):

​

29

Table of Contents

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Less Than |  | ​ | ​ |  | ​ |  | More than |
​ | ​ | Total | ​ | 1 Year | ​ | 1 to 3 Years | ​ | 3 to 5 Years | ​ | 5 Years |
Operating lease obligations (1) | ​ | $ | 32,654 | ​ | $ | 12,929 | ​ | $ | 18,186 | ​ | $ | 1,539 | ​ | $ | — | ​
Total | ​ | $ | 32,654 | ​ | $ | 12,929 | ​ | $ | 18,186 | ​ | $ | 1,539 | ​ | $ | — | ​

​

| (1) | Represents future minimum lease payments under our non-cancelable operating leases. The minimum lease payments above exclude our share of the facility operating expenses and other costs that are reimbursable to the landlord under the leases.

​

The table above does not include potential milestone and success fees, sublicense fees, royalty fees, licensing maintenance fees, and reimbursement of patent maintenance costs that we may be required to pay under agreements we have entered into with certain institutions to license intellectual property. Our agreements to license intellectual property include potential milestone payments that are dependent upon the development of products using the intellectual property licensed under the agreements and contingent upon the achievement of development or regulatory approval milestones, as well as commercial milestones. We have not included such potential obligations in the table above because they are contingent upon the occurrence of future events and the timing and likelihood of such potential obligations are not known with certainty. For further information regarding these agreements, please see “Business—Our Collaborations and Licensing Strategy” in our Annual Report.

​

We enter into contracts in the normal course of business with contract research organizations and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations and commitments.

​

Off-Balance Sheet Arrangements

​

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

​

Effects of Inflation

​

Inflation would generally affect our business by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the nine months ended September 30, 2021 or 2020.

​

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

​

We are exposed to market risk related to changes in interest rates. As of September 30, 2021, we had cash and cash equivalents of $259.9 million, primarily held in money market mutual funds consisting of U.S. government-backed securities, and marketable securities of $298.0 million, primarily consisting of U.S. government-backed securities and corporate debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form, or may be in the form of, money market funds or marketable securities and are or may be invested in U.S. Treasury and U.S. government agency obligations. Due to the short-term maturities and low risk profiles of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our investments.

While we contract with certain vendors and institutions internationally, substantially all of our total liabilities as of September 30, 2021 were denominated in the United States dollar and we believe that we do not have any material exposure to foreign currency exchange rate risk.

​

30

Table of Contents

Item 4. Controls and Procedures.

​

Evaluation of Disclosure Controls and Procedures

​

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

​

Changes in Internal Control over Financial Reporting

​

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

31

Table of Contents

PART II. OTHER INFORMATION

​

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. There can be no assurance that any proceedings that result from these third-party actions will be resolved in our favor. In addition, if they are not resolved in our favor, there can be no assurance that the result will not have a material adverse effect on our business, financial condition, results of operations, or prospects. Certain of our intellectual property rights, including ones licensed to us under our licensing agreements, are subject to, and from time to time may be subject to, priority and validity disputes. For additional information regarding these matters, see Part I, “Item 1A. Risk Factors—Risks Related to Our Intellectual Property” in our Annual Report and Part II, “Item 1A. Risk Factors” in this Quarterly Report on Form 10-Q. Regardless of outcome, litigation or other legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

​

Item 1A. Risk Factors.

​

You should carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed below and in the sections entitled “Summary of Risk Factors” and “Risk Factors” in our Annual Report, which could materially affect our business, financial condition, results of operations, or prospects. These risks, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our common stock. Additional risks not currently known to us or that we currently deem to be immaterial may also harm our business.

Some of our in-licensed patents are subject to priority and validity disputes. In addition, our owned and in-licensed patents, patent applications and other intellectual property may be subject to further priority and validity disputes, and other similar intellectual property proceedings including inventorship disputes. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we develop, which could have a material adverse impact on our business.

Certain U.S. patents and a U.S. patent application directed to CRISPR/Cas9 that are co-owned by the Broad and the Massachusetts Institute of Technology (“MIT”), and in some cases Harvard (collectively referred to as “Broad”), and in-licensed by us were involved in a first interference with a U.S. patent application that is co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively referred to “CVC”). An interference is a proceeding in the USPTO before the Patent Trial and Appeal Board of the USPTO (“PTAB”) to determine priority of invention of the subject matter of patent claims filed by different parties. In this first interference, the PTAB made a judgment of no interference-in-fact in favor of the Broad, which was upheld on appeal. This decision was final and bars any further interference between the same parties for claims to the same invention that was considered in the interference. As a result of this decision, the U.S. patents and application that we in-license from the Broad and others were not modified or revoked.

On June 24, 2019, the PTAB declared a second interference between certain pending U.S. patent applications that are co-owned by CVC and certain U.S. patents and a U.S. patent application that are co-owned by Broad and in-licensed by us. Most of the Broad U.S. patents and the patent application that are involved in the second interference were also part of the first interference. The invention that was considered in the first interference related to a method involving contacting a target DNA in a eukaryotic cell with certain defined CRISPR/Cas9 components for the purpose of cleaving or editing that target DNA molecule or modulating transcription of at least one gene encoded thereon. The second interference is directed to a different invention, namely a eukaryotic cell comprising a target DNA and certain defined CRISPR/Cas9 components including a single molecule guide RNA that are capable of cleaving or editing the target DNA molecule.

32

Table of Contents

On September 10, 2020, the PTAB granted Broad’s motion for priority benefit while denying CVC priority benefit to their two earliest provisional patent applications. As a result, Broad entered the priority phase of the interference as “Senior Party” while CVC remained the “Junior Party” for purposes of determining which entity was the first to invent the inventions at issue. We cannot predict with any certainty how long it will take before the PTAB issues a decision at the conclusion of the priority phase.

On December 14, 2020, the PTAB, declared two new interferences involving a pending U.S. patent application that is owned by ToolGen, Inc. (the “ToolGen application”). One of the two interferences is between the ToolGen application and certain U.S. patents and U.S. patent applications that are co-owned by Broad and in-licensed by us. Most of the Broad U.S. patents and patent applications that are involved in the interference with ToolGen are also part of the second interference with CVC. The other ToolGen interference is between the same ToolGen application and the U.S. patent applications that are co-owned by CVC and involved in the second interference with Broad. The claims in ToolGen’s patent application relate to a mammalian cell with a CRISPR/Cas system comprising a codon optimized nucleic acid encoding a Cas9 polypeptide with a nuclear localization signal and a single-molecule guide RNA that, together, are capable of forming a Cas9/RNA complex that mediates double stranded cleavage of a target nucleic acid sequence.

On June 21, 2021, the PTAB declared two new patent interferences involving a pending U.S. patent application owned by Sigma-Aldrich (the “Sigma-Aldrich application”). One of the two new patent interferences is between the Sigma-Aldrich application and certain U.S. patents and U.S. patent applications that are co-owned by Broad and in-licensed by us. The second new patent interference is between the same Sigma-Aldrich application and the U.S. patent applications that are co-owned by CVC. Most of the Broad U.S. patents and patent applications that are involved in the interference with Sigma-Aldrich are also part of the concurrent interferences with CVC and ToolGen. The claims in Sigma-Aldrich’s application relate to a method for modifying a chromosomal sequence in a eukaryotic cell by integrating a donor sequence into that chromosomal sequence. These methods use a CRISPR/Cas9 system comprising a Cas9 polypeptide with a nuclear localization signal, a guide RNA, and a donor sequence that, together, are capable of mediating double stranded cleavage and repair of a target nucleic acid sequence leading to integration of the donor sequence into the chromosomal sequence.

As a result of these declarations of interference, five parallel adversarial proceedings in the USPTO before the PTAB have been initiated – the patent interferences between Broad and CVC, Broad and ToolGen, CVC and ToolGen, Broad and Sigma-Aldrich, and CVC and Sigma-Aldrich. We cannot predict with any certainty how long each interference proceeding will take. It is also possible that other third parties may seek to become a party to these interferences.

Our owned and in-licensed patents and patent applications are, or may in the future become, subject to validity disputes in the USPTO and other foreign patent offices. For example, a request for ex parte re-examination was filed with the USPTO on February 16, 2016 against a U.S. patent that we have in-licensed from Broad, which is involved in certain of the interferences. The request for ex parte re-examination was granted on May 9, 2016 thereby initiating a re-examination procedure between the USPTO and The Broad Institute, acting on behalf of itself and MIT. The PTAB has suspended the re-examination noting that it has jurisdiction over any file that involves a patent involved in an interference. It is uncertain when the PTAB will lift the suspension. If The Broad Institute is unsuccessful during the re-examination, the patent in question may be revoked or narrowed, which could have a material adverse effect on the scope of our rights under such patent.

We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned or in-licensed patents or patent applications, or other intellectual property rights as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents, patent applications or other intellectual property rights, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents, including any patents that issue from patent applications, against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on the conduct of our business, financial condition, results of operations, and prospects.

33

Table of Contents

We or our licensors are subject to and may in the future become a party to similar proceedings or priority disputes in Europe or other foreign jurisdictions. For example, certain European patents that we have in-licensed from Broad have been revoked in their entirety by the European Patent Office Opposition Division (the “Opposition Division”). Certain other European patents that we have in-licensed from Broad were maintained with amended patent claims. Certain of these decisions have been appealed by both Broad and the opposing party(s), and it is uncertain when or in what manner the Boards of Appeal will act on these appeals. The Opposition Division has also initiated opposition proceedings against certain other European patents that we have in-licensed from Broad. The EPO opposition proceedings may involve issues including, but not limited to, procedural formalities related to filing the European patent application, priority, and the patentability of the involved claims. In view of certain arguments made by the third parties against the revoked patents and similar arguments made by the third parties against other in-licensed European patents under opposition, the opposition proceedings may lead to the revocation of certain additional in-licensed European patents. The loss of priority for, or the loss of, these European patents could have a material adverse effect on the conduct of our business. One or more of the third parties that have filed oppositions against these European patents or other third parties may file future oppositions against other European patents that we in-license or own. There may be other oppositions against these European patents that have not yet been filed or that have not yet been made available to the public.

If we or our licensors are unsuccessful in any patent related disputes, including interference proceedings, patent oppositions, re-examinations, or other priority, inventorship, or validity disputes to which we or they are subject (including any of the proceedings discussed above), we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated, or held unenforceable. In addition, if we or our licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or in-licensed patents and patent applications. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or may be non-exclusive or may not be available at all. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we develop. The loss of exclusivity or the narrowing of our owned and in-licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in any interference proceeding or other priority, inventorship, or validity disputes, it could result in substantial costs and be a distraction to our management and other employees.

​

​

​

​

​

34

Table of Contents

Item 6. Exhibits

​

Exhibit Index

​

Exhibit Number |  | Description of Exhibit
10.1* | ​ | Employment Offer Letter, dated Se ptember 22, 2021, between the Registrant and B ruce Eaton
10.2*† | ​ | License Agreement, dated August 29, 2014, between the Registrant and The General Hospital Corporation, d/b/a Massachusetts General Hospital
10.3*† | ​ | Second Amendment to the Exclusive Patent License Agreement, by and between the Company and The General Hospital Corporation, d/b/a Massachusetts General Hospital, dated November 17, 2016
10.4*† | ​ | License Agreement, dated October 10, 2014, between the Registrant and Duke University
10.5*† | ​ | Letter Agreement, dated October 9, 2015, between the Registrant and Duke University
10.6*† | ​ | License Agreement, dated October 29, 2014, among the Registrant, the President and Fellows of Harvard College, and the Broad Institute, Inc.
10.7*† | ​ | License and Collaboration Agreement, dated May 26, 2015, between the Registrant and Juno Therapeutics, Inc.
31.1* | ​ | Rule 13a-14(a) Certification of Principal Executive Officer
31.2* | ​ | Rule 13a-14(a) Certification of Principal Financial Officer
32.1+ | ​ | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350
101* | ​ | The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets (unaudited), (ii) Consolidated Statements of Operations (unaudited), (iii) Consolidated Statements of Comprehensive Loss (unaudited), (iv) Consolidated Statements of Stockholders’ Equity (unaudited), (v) Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.
104* | ​ | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline XBRL. ​

​

* Filed herewith

† Filed with this Quarterly Report on Form 10-Q solely for the purpose of transitioning these previously-filed exhibits, which are the subject of expiring confidential treatment orders, to the rules governing the filing of redacted exhibits under Regulation S-K Item 601(b)(10)(iv) pursuant to the SEC’s CF Disclosure Guidance: Topic 7. Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

+ The certifications furnished in Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications are not to be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.

​

​

35

Table of Contents

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​ | ​ | ​
​ | EDITAS MEDICINE, INC.
​ | ​ | ​
​ | ​ | ​
Dated: November 9, 2021 | By: | /s/ Michelle Robertson
​ | ​ | Michelle Robertson
​ | ​ | Chief Financial Officer (Principal Financial Officer)

​

​

​

​

36